Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
The hardest part of working out consistently? Getting started. Once you do, though, you start feeling (and soon, seeing!) the positive impact on your mind and body. But with so many workout options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results